Logo image of MPH.CA

MEDICURE INC (MPH.CA) Stock Price, Quote, News and Overview

TSX-V:MPH - TSX Venture Exchange - CA58469E4085 - Common Stock - Currency: CAD

0.83  -0.12 (-12.63%)

MPH.CA Quote, Performance and Key Statistics

MEDICURE INC

TSX-V:MPH (4/30/2025, 7:00:00 PM)

0.83

-0.12 (-12.63%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.56
52 Week Low0.63
Market Cap8.67M
Shares10.44M
Float7.65M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)04-28 2025-04-28/amc
IPO03-30 1999-03-30


MPH.CA short term performance overview.The bars show the price performance of MPH.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

MPH.CA long term performance overview.The bars show the price performance of MPH.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of MPH.CA is 0.83 CAD. In the past month the price increased by 5.06%. In the past year, price decreased by -47.8%.

MEDICURE INC / MPH Daily stock chart

MPH.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
EDT.CA SPECTRAL MEDICAL INC N/A 250.91M
FRX.CA FENNEC PHARMACEUTICALS INC N/A 249.41M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 193.59M
TH.CA THERATECHNOLOGIES INC N/A 165.99M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 82.91M
COV.CA COVALON TECHNOLOGIES LTD 15.47 72.11M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 66.23M
BLU.CA BLUENERGIES LTD N/A 58.33M
ONC.CA ONCOLYTICS BIOTECH INC N/A 56.81M
SVA.CA SERNOVA BIOTHERAPEUTICS INC N/A 51.14M
HBP.CA HELIX BIOPHARMA CORP N/A 50.90M
MBX.CA MICROBIX BIOSYSTEMS INC 36 50.77M

About MPH.CA

Company Profile

MPH logo image Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 25 full-time employees. The company is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. The company also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. The company also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

Company Info

MEDICURE INC

1250 Waverley Street

Winnipeg MANITOBA R3T 6C6 CA

CEO: Albert D. Friesen

Employees: 25

MPH Company Website

MPH Investor Relations

Phone: 12044877412

MEDICURE INC / MPH.CA FAQ

What is the stock price of MEDICURE INC today?

The current stock price of MPH.CA is 0.83 CAD. The price decreased by -12.63% in the last trading session.


What is the ticker symbol for MEDICURE INC stock?

The exchange symbol of MEDICURE INC is MPH and it is listed on the TSX Venture Exchange exchange.


On which exchange is MPH.CA stock listed?

MPH.CA stock is listed on the TSX Venture Exchange exchange.


What is MEDICURE INC worth?

MEDICURE INC (MPH.CA) has a market capitalization of 8.67M CAD. This makes MPH.CA a Nano Cap stock.


How many employees does MEDICURE INC have?

MEDICURE INC (MPH.CA) currently has 25 employees.


What are the support and resistance levels for MEDICURE INC (MPH.CA) stock?

MEDICURE INC (MPH.CA) has a support level at 0.82 and a resistance level at 0.84. Check the full technical report for a detailed analysis of MPH.CA support and resistance levels.


Should I buy MEDICURE INC (MPH.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does MEDICURE INC (MPH.CA) stock pay dividends?

MPH.CA does not pay a dividend.


When does MEDICURE INC (MPH.CA) report earnings?

MEDICURE INC (MPH.CA) will report earnings on 2025-04-28, after the market close.


What is the Price/Earnings (PE) ratio of MEDICURE INC (MPH.CA)?

MEDICURE INC (MPH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).


MPH.CA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to MPH.CA. When comparing the yearly performance of all stocks, MPH.CA is a bad performer in the overall market: 89.56% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MPH.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MPH.CA. While MPH.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MPH.CA Financial Highlights

Over the last trailing twelve months MPH.CA reported a non-GAAP Earnings per Share(EPS) of -0.19. The EPS decreased by -289.86% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -7.14%
ROE -10.18%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%805.56%
Sales Q2Q%6.34%
EPS 1Y (TTM)-289.86%
Revenue 1Y (TTM)-8.09%

MPH.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 40% to MPH.CA. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners23.1%
Ins Owners26.23%
Short Float %N/A
Short RatioN/A
Analysts
Analysts40
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A